<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nutriband Inc — News on 6ix</title>
<link>https://6ix.com/company/nutriband-inc</link>
<description>Latest news and press releases for Nutriband Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nutriband-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a3e378dffbe2df10a685.webp</url>
<title>Nutriband Inc</title>
<link>https://6ix.com/company/nutriband-inc</link>
</image>
<item>
<title>Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-ceo-gareth-sheridan-discusses-the-us-fentanyl-crisis-and-company-update-on-latest-episode-of-the-jack-neel-podcast</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-ceo-gareth-sheridan-discusses-the-us-fentanyl-crisis-and-company-update-on-latest-episode-of-the-jack-neel-podcast</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company’s AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications. Interested shareholders may find the link to the latest youtube episode here https://youtu.be/HB6E7TxGXqg?si=VU6c57saNbdzxraH. Th</description>
</item>
<item>
<title>Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-selects-commercial-brand-name-for-its-abuse-deterrent-fentanyl-patch</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-selects-commercial-brand-name-for-its-abuse-deterrent-fentanyl-patch</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA</description>
</item>
<item>
<title>Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-ai-kinesiology-tapes-approved-for-distribution-and-sale-in-costa-rica</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-ai-kinesiology-tapes-approved-for-distribution-and-sale-in-costa-rica</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company recently announced an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products and Mosquito repellent</description>
</item>
<item>
<title>Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-signs-exclusive-distribution-agreement-122800648</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-signs-exclusive-distribution-agreement-122800648</guid>
<pubDate>Tue, 17 Feb 2026 12:28:00 GMT</pubDate>
<description>ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch. About AVERSA™ Abuse-Deterrent Tra</description>
</item>
<item>
<title>Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-provides-summary-annual-120000341</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-provides-summary-annual-120000341</guid>
<pubDate>Fri, 30 Jan 2026 12:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below. Addition of Two New Directors Allesandro PudduAlessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial re</description>
</item>
<item>
<title>Nutriband CEO Publishes Letter to Shareholders</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-ceo-publishes-letter-shareholders-120000367</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-ceo-publishes-letter-shareholders-120000367</guid>
<pubDate>Wed, 31 Dec 2025 12:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and</description>
</item>
<item>
<title>Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-signs-agreement-sell-140000037</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-signs-agreement-sell-140000037</guid>
<pubDate>Mon, 29 Dec 2025 14:00:00 GMT</pubDate>
<description>Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has sign</description>
</item>
<item>
<title>Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-signs-letter-intent-130000697</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-signs-letter-intent-130000697</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum TechnologyORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Fou</description>
</item>
<item>
<title>Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-differentiates-prescription-fentanyl-illicit-120000189</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-differentiates-prescription-fentanyl-illicit-120000189</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the manufacture and distribution by cartels and foreign networks that have flooded the US with illegal f</description>
</item>
<item>
<title>Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-2025-noble-120000363</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-2025-noble-120000363</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Wednesday, December 3rd at 9.30 AM Eastern Standard Time.Interested investors and guests of Nutriband Inc. are welcome to attend at a...</description>
</item>
<item>
<title>REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch</title>
<link>https://6ix.com/company/nutriband-inc/news/repeat-nutriband-announces-successful-meeting-150500021</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/repeat-nutriband-announces-successful-meeting-150500021</guid>
<pubDate>Tue, 28 Oct 2025 15:05:00 GMT</pubDate>
<description>Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product. ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW),</description>
</item>
<item>
<title>Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-announces-successful-meeting-completed-110000683</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-announces-successful-meeting-completed-110000683</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product. ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW),</description>
</item>
<item>
<title>Nutriband Co-Founder Gareth Sheridan Returns as CEO</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-co-founder-gareth-sheridan-110000920</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-co-founder-gareth-sheridan-110000920</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO effective immediately and will guide the company through the final 2025 framework towards the target NDA filing in 2026 for AVERSA Fentanyl. AVER</description>
</item>
<item>
<title>Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-signs-agreement-brand-institute-110000976</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-signs-agreement-brand-institute-110000976</guid>
<pubDate>Fri, 10 Oct 2025 11:00:00 GMT</pubDate>
<description>Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development. ORLANDO, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that through its 4P Therapeut</description>
</item>
<item>
<title>Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-files-provisional-patent-application-123000745</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-files-provisional-patent-application-123000745</guid>
<pubDate>Wed, 08 Oct 2025 12:30:00 GMT</pubDate>
<description>Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure. ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the develop</description>
</item>
<item>
<title>Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-present-noble-capital-markets-103000408</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-present-noble-capital-markets-103000408</guid>
<pubDate>Wed, 08 Oct 2025 10:30:00 GMT</pubDate>
<description>ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, October 8 at 15:00 Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Scheduled 1x1 meetings with Mr. Melnik are also available for registered, qualified investor atte</description>
</item>
<item>
<title>Nutriband Inc. to Present at the MicroCap Rodeo Conference</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-microcap-rodeo-200500236</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-microcap-rodeo-200500236</guid>
<pubDate>Wed, 24 Sep 2025 20:05:00 GMT</pubDate>
<description>Thursday, September 25, 2025 in New York CityORLANDO, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (The Company) (Nasdaq:NTRB) (Nasdaq: NTRBW), announces it will participate in the MicroCap Rodeo Conference, to be held Thursday, June 25, 2025, in New York City. For example: Company Chairman, Serguei Melnik, will be attending the conference to discuss the company’s operational highlights, growth initiatives, and strategic direction for its platform technology AVERSA. The presentation w</description>
</item>
<item>
<title>Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-quarterly-report-highlights-131500139</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-quarterly-report-highlights-131500139</guid>
<pubDate>Wed, 10 Sep 2025 13:15:00 GMT</pubDate>
<description>ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. Th</description>
</item>
<item>
<title>Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-announces-exercise-warrants-200100405</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-announces-exercise-warrants-200100405</guid>
<pubDate>Wed, 03 Sep 2025 20:01:00 GMT</pubDate>
<description>ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000. The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to b</description>
</item>
<item>
<title>Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025</title>
<link>https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-emerging-growth-130000340</link>
<guid isPermaLink="true">https://6ix.com/company/nutriband-inc/news/nutriband-inc-present-emerging-growth-130000340</guid>
<pubDate>Mon, 18 Aug 2025 13:00:00 GMT</pubDate>
<description>Nutriband Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth ConferenceORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq: NTRB) (the “Company”) is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will gi</description>
</item>
</channel>
</rss>